Cowen and Company Reaffirms Hold Rating for Qiagen N.V. (QGEN)

Cowen and Company reiterated their hold rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research note published on Friday, November 3rd. The brokerage currently has a $33.00 price target on the stock.

A number of other research firms also recently weighed in on QGEN. Zacks Investment Research downgraded shares of Qiagen N.V. from a buy rating to a hold rating in a research note on Tuesday, August 1st. BidaskClub upgraded shares of Qiagen N.V. from a hold rating to a buy rating in a research report on Wednesday, July 19th. Wells Fargo & Company restated a market perform rating and set a $31.00 price target (up previously from $28.00) on shares of Qiagen N.V. in a report on Thursday, July 13th. Jefferies Group LLC restated a hold rating and set a $28.00 price target (up previously from $25.00) on shares of Qiagen N.V. in a report on Monday, July 31st. Finally, Commerzbank Ag restated a buy rating on shares of Qiagen N.V. in a report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. Qiagen N.V. presently has a consensus rating of Hold and an average price target of $34.06.

Qiagen N.V. (NASDAQ QGEN) traded down $0.25 during trading hours on Friday, reaching $31.87. 1,014,173 shares of the company were exchanged, compared to its average volume of 971,728. Qiagen N.V. has a 1-year low of $27.51 and a 1-year high of $36.34. The company has a market capitalization of $7,128.04, a price-to-earnings ratio of 25.45, a price-to-earnings-growth ratio of 1.92 and a beta of 1.13. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68.

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.32. The firm had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share. analysts anticipate that Qiagen N.V. will post 1.25 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cowen and Company Reaffirms Hold Rating for Qiagen N.V. (QGEN)” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/cowen-and-company-reaffirms-hold-rating-for-qiagen-n-v-qgen/1756106.html.

Several large investors have recently modified their holdings of QGEN. BlackRock Inc. boosted its holdings in shares of Qiagen N.V. by 8,793.4% in the 1st quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Atlanta Capital Management Co. L L C raised its stake in Qiagen N.V. by 210.1% in the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock valued at $41,400,000 after acquiring an additional 890,454 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Qiagen N.V. in the 2nd quarter valued at about $26,408,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Qiagen N.V. in the 2nd quarter valued at about $18,234,000. Finally, WINTON GROUP Ltd bought a new stake in Qiagen N.V. in the 2nd quarter valued at about $15,088,000. 59.96% of the stock is currently owned by institutional investors.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.